Biodol Therapeutics, a portfolio company of V-Bio Ventures, has nominated its first preclinical candidate for neuropathic pain. The candidate is a small-molecule allosteric FLT3 inhibitor, suitable for chronic oral administration and without the safety limitations of less specific intracellular kinase inhibitors.
Target ALS Foundation Inc. and the Alzheimer's Drug Discovery Foundation LLC (ADDF) have announced the first four award recipients in a new initiative to identify and develop biomarkers for neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD).
In the steadily heating-up psychedelics space, Wall Street is closely watching a number of players, among them Compass Pathways plc, which has slated an R&D update for Oct. 12. The check-in could provide guidance for investors on how the FDA regards COMP-360, the firm’s oral psilocybin for treatment-resistant depression (TRD). It could also help observers guess about the fate of pipeline prospects in the hands of others, including GH Research plc, advancing a would-be TRD fix derived from dried venom secreted by the Bufo alvarius toad.
Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.
Gate Neurosciences Inc. was first founded in 2019, but officially launched last week with two clinical-stage assets and a bold goal: to develop better drugs for CNS disorders and identify better-suited patients for those drugs. The company’s first molecular target is the NMDA receptor. Gate has acquired the rights to two NMDA receptor modulators, zelquistinel and apimostinel.
Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.
As Novartis AG works to streamline the company and finalized a long-considered plan to separate its Sandoz Inc. business by creating a standalone company, it temporarily stopped dosing in a study of branaplam for treating Huntington’s disease. Several findings from the phase IIb study suggested the presence of peripheral neuropathy in some participants. An independent data monitoring committee recommended the dosing halt but fell short of recommending the study be terminated. The VIBRANT-HD steering committee agreed with the committee’s recommendation.
Trigeminal neuralgia is a debilitating chronic neuropathy characterized by sudden, short and intense episodes of shooting, stabbing or shock-like pain in the face. To date, there is still an incomplete understanding of the pathophysiologic molecular mechanisms behind trigeminal neuralgia and the search for molecular targets is of medical need.
Seelos Therapeutics has been selected to receive a grant from The Michael J. Fox Foundation (MJFF) for Parkinson's Research to advance preclinical research and development of its gene therapy delivered SLS-004 program.
RSS
